Novavax: Nuvaxovid Approved In South Korea As Booster For Active Immunization To Prevent COVID-19

Novavax, Inc. (NVAX) said its partner SK bioscience has received expanded manufacturing and marketing approval from the Korean Ministry of Food and Drug Safety for Nuvaxovid for use as a booster for active immunization to prevent COVID-19 in adults aged 18 and older. The approval is based on data from Novavax' Phase 2 trial conducted in the U.S. and Australia, from a separate Phase 2 trial conducted in South Africa, and from the United Kingdom-sponsored COV-BOOST trial.

Novavax' COVID-19 vaccine is authorized for use as an adult booster in more than 35 countries. In Korea, SK bioscience signed a licensing agreement with Novavax and is manufacturing drug substance and drug product of Nuvaxovid for domestic use.

For More Such Health News, visit rttnews.com.

For comments and feedback contact: editorial@rttnews.com

Business News

Follow RTT